Radiology Doctors in Sedona, AZ Accepting Medicare

3 Radiology doctors found. Showing 1 - 3

David C Beyer, MD Radiology - Radiation Oncology Medicare: Accepting Medicare Assignments Practice Location: 3700 W State Route 89a, Verde Valley Medical Center - Sedona, Sedona, AZ 86336 Phone: 928-204-4160    Fax: 602-483-1304

Richard Harry Saul, M.D. Radiology - Diagnostic Radiology Medicare: Not Enrolled in Medicare Practice Location: 155 Shadow Rock Dr, Sedona, AZ 86336 Phone: 928-282-2814

James Daniel Cates, M.D. Radiology - Diagnostic Radiology Medicare: Not Enrolled in Medicare Practice Location: 70 Ranch Road, Sedona, AZ 86336 Phone: 928-282-5374

News Archive

Breast-feeding may aid development of white matter structures in the brains of premature babies

To the growing list of reasons why mothers should consider breast-feeding infants, add another: Critical white matter structures in the brains of babies who are born so prematurely that they weigh less than 1,500 grams develop more robustly when their mothers breast-feed them, compared with preemie peers who are fed formula.

Patients with muscular dystrophy mount immune response to dystophin protein prior to gene therapy: Study

A clinical trial designed to replace the genetic defect causing the most common form of muscular dystrophy has uncovered an unexpected aspect of the disease. The trial, based on therapy designed by scientists at the University of North Carolina at Chapel Hill School of Medicine, showed that some patients mount an immune response to the dystrophin protein even before they have received the gene therapy.

Patients question how FDA approves medical devices

There's no doubt that surgically implanted medical devices can improve lives. Hip and knee replacements can help people regain their mobility. Drug pumps can deliver doses of pain-relieving medicine on demand. And metal rods can stabilize spines and broken bones.

Anthera Pharmaceuticals reaches agreement with the FDA on SPA for VISTA-16 clinical study

Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) for its lead product candidate, A-002, an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome.

Research provides new framework for quantifying risk of avian-borne diseases

In 2005 an outbreak of the H5N1 'bird flu' virus in South East Asia led to widespread fear with predictions that the intercontinental migration of wild birds could lead to global pandemic.

Read more Medical News

› Verified 4 days ago